What Is Retatrutide? NP-III (RT) Triple Agonist Research Guide

Retatrutide (research code LY3437943) is an investigational peptide developed by Eli Lilly that activates three metabolic hormone receptors — GIP, GLP-1, and glucagon — in a single molecule. Nicknamed the “triple G” agonist, it is the first triple incretin-based candidate to reach Phase 3 clinical trials, and its published results have made it one of the most studied compounds in metabolic research.

At NUPEPS, research-grade retatrutide is supplied as NP-III (RT) — lyophilized, batch-tested, and sold strictly for laboratory research use.

Scope note: Retatrutide is an investigational compound. It is not approved by the FDA or any regulatory authority, and NUPEPS products are sold for in vitro and analytical research only — never for human or veterinary use.

What Is Retatrutide?

Retatrutide is a synthetic peptide engineered from the human GIP (glucose-dependent insulinotropic polypeptide) sequence, modified to also activate the GLP-1 (glucagon-like peptide-1) and glucagon receptors. It is administered as a single molecule — not a blend of three drugs — which is what makes it “first-in-class” among multi-agonist metabolic candidates.

The compound originated in Eli Lilly’s incretin research program as LY3437943 and entered human trials in the early 2020s. It is currently in the Phase 3 TRIUMPH program, with an FDA filing expected and a regulatory decision anticipated in 2027 or early 2028.

The Triple Agonist Mechanism

Each of the three receptor targets contributes a distinct pharmacological action, studied extensively in receptor-binding and animal-model research:

• GIP receptor — glucose-dependent insulinotropic polypeptide signaling; studied for its role in insulin secretion, lipid metabolism, and adipocyte function.
• GLP-1 receptor — the incretin pathway shared with semaglutide and tirzepatide; studied for effects on satiety signaling, gastric emptying, and glucose-dependent insulin release.
• Glucagon receptor — the distinguishing third target; studied for its role in hepatic fatty acid oxidation and energy expenditure, pathways absent from single- and dual-agonist molecules.

The research hypothesis behind the triple design: combining appetite and glycemic signaling (GIP/GLP-1) with increased energy expenditure (glucagon) produces greater metabolic effects than either pathway alone. Preclinical receptor-activation studies confirmed balanced agonism across all three targets before the molecule advanced to human trials.

Retatrutide vs. Tirzepatide vs. Semaglutide

The key research distinction: tirzepatide is a dual agonist and semaglutide a single agonist, while retatrutide adds glucagon-receptor activity — the component researchers associate with the energy-expenditure signal.

Published Clinical Research

All of the following are published or company-reported clinical trial results, presented here as research data — not as claims about any research-use product:

• Phase 2 (NEJM, 2023): 48-week randomized trial in 338 adults with obesity (no diabetes). The 12 mg weekly dose produced up to 24% mean weight reduction at 48 weeks (17.5% at the 24-week primary endpoint).
• TRIUMPH-4 (Phase 3, 2025): adults with obesity and knee osteoarthritis; up to 28.7% mean weight loss (71.2 lbs) at 68 weeks on the highest doses.
• TRIUMPH-2 (Phase 3): adults with obesity and type 2 diabetes; 20.8% mean weight reduction at 80 weeks on 12 mg.
• TRANSCEND-T2D-1 (Phase 3, 2026): adults with type 2 diabetes; A1C reductions of 1.7–2.0 percentage points and weight reductions of 11.5–16.8% at 40 weeks.

Reported adverse events in trials were predominantly gastrointestinal (nausea, diarrhea, vomiting), mostly during dose escalation — consistent with the incretin drug class. The safety profile remains under investigation, which is precisely why the compound is still classified as investigational.

Investigational Status

To state it plainly: retatrutide is not FDA approved. It is available to researchers only through clinical trials and research-supply channels. Any product marketed for human use is unapproved and unverified — Eli Lilly has pursued legal action against vendors selling unapproved versions of the compound.

For laboratories, this status makes verified material quality essential. Research conducted with mislabeled or impure material produces unreliable data, regardless of the compound’s promise in registered trials.

Retatrutide in the Laboratory

Like most research peptides, retatrutide ships as a lyophilized powder and requires careful handling:

• Verify identity and purity against the batch-specific COA before use — our guide on how to read a peptide COA walks through HPLC and mass-spec sections.
• Reconstitute with sterile technique using an appropriate diluent; see our step-by-step reconstitution guide.
• Store correctly — lyophilized at −20 °C long term; reconstituted aliquots refrigerated short term or frozen single-use. Details in our peptide storage guide.

NP-III (RT) at NUPEPS

NUPEPS supplies research-grade retatrutide as NP-III (RT) in multiple vial sizes. Every batch is third-party tested for purity, quantity, and sterility, with batch-specific COAs verifying 99%+ purity.

Browse the full catalog of research peptides or see how NUPEPS tests every batch.

Frequently Asked Questions

What does “triple agonist” mean?

It means the molecule activates three hormone receptors — GIP, GLP-1, and glucagon — rather than one or two. Retatrutide is the first triple incretin-based agonist to reach Phase 3 trials.

Is retatrutide FDA approved?

No. As of 2026, retatrutide remains investigational. Eli Lilly is expected to file for FDA approval with a decision anticipated in 2027 or early 2028.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors (GIP and GLP-1); retatrutide adds a third (glucagon). Both are Eli Lilly compounds; tirzepatide is FDA approved, retatrutide is not.

What is NP-III (RT)?

NP-III (RT) is NUPEPS’ catalog name for research-grade retatrutide — lyophilized, COA-verified, and sold strictly for laboratory research use.

How should retatrutide be stored in the lab?

Lyophilized vials: freezer (−20 °C) for long-term storage. After reconstitution: refrigerate short term or freeze single-use aliquots; never repeatedly freeze–thaw. See our peptide storage guide.

Conclusion

Retatrutide represents the cutting edge of incretin-based metabolic research — a single molecule engaging three receptor systems, with Phase 3 data that researchers continue to analyze. For laboratories studying this compound, material quality is the foundation: verified identity, documented purity, and disciplined handling from vial to assay.

Common questions about ordering and shipping are answered in our FAQs.

Research Use Only disclaimer: All NUPEPS products, including NP-III (RT), are sold strictly for laboratory and in vitro research use only. They are not intended for human or veterinary use, nor for the diagnosis, treatment, cure, or prevention of any disease. Retatrutide is an investigational compound not approved by the FDA. This article is for informational purposes only; it does not constitute medical or scientific advice.

Further reading: How to Reconstitute Lyophilized Peptides · Peptide Storage Guide · How to Read a Peptide COA · What Is MOTS-C? Complete Research Guide